leisure time -WSS

leisure time

author：leisure time 2025-09-30 00:35:51 - browse：9418

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Medicare Advantage insurers pressure Biden for bigger payments

WSS

Yancopoulos of Regeneron works to expand Dupixent success

Cancer researcher Catriona Jamieson is sending tumors into space

'Patient friction coefficient' can gauge a clinical trial's patient burden

Testing GLP

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Cholera vaccine supply gets boost as demand surges globally

Wikipedia

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

Bring on the sabbaticals for nurses

In Memoriam: Notable people who died in 2023

Surgeons perform first xenotransplant using CRISPR'd pig kidney

At least 13 dead in Texas as scorching temps continue

Health care needs a new profession: neuroimaging counseling

Walensky prepares to leave CDC — and Congress — behind

Bird flu in milk supply is likely coming from asymptomatic cows

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Illumina, CRISPR, Regeneron

leisure time

Yancopoulos of Regeneron works to expand Dupixent success

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Why rehabilitation engineers need to center patients in their research

Mirador, a new biotech startup, launches with $400 million

U.K. officials, researchers try to ease path for bespoke genetic treatments

Health care needs a new profession: neuroimaging counseling

entertainment

focus

leisure time

knowledge